Conference Day Two

Thursday, April 3

7:30 am Check-In & Coffee Networking

8:25 am Chair’s Opening Remarks

Pioneering TCR Applications Beyond Oncology to Expand Treatment Potential

8:30 am Expanding TCR Therapy Success by Pursuing Autoimmune Treatments

Synopsis

• Taking learnings in TCR efficacy and safety from oncology and applying to optimize

• Evaluating your approach characteristics to determine the most suitable target indication

• Balancing durability and safety in non-oncology patient populations

9:00 am Harnessing TCR Bispecifics to Tackle Autoimmune Diseases

Synopsis

• Adapting the ImmTAX platform to address autoimmune diseases

• First clinical programme for the treatment of Type I diabetes

Unlocking the Next-Generation of TCR-Based Therapies

9:30 am Pioneering Artificial Intelligence & Machine Learning to Turbocharge TCR Therapy Development

Synopsis

• Developing AI to rapidly screen TCR molecules to predict target binding

• Accelerating screening of TCR libraries to identify effective TCR molecules with minimal off-target effects

• Utilizing AI to influence the design for optimal synthetic TCR molecules

10:00 am Morning Refreshment Break & Networking

11:00 am TCR-Guided Therapies to Match Individual Patient Needs

Synopsis

• We develop three TCR-guided modalities, TCR-T cells, TCR-NK cells, and TCR-TCEs, based on our 3S TCR technologies.

• We assemble a library of 3S TCRs of different antigen specificity and HLA restriction to meet needs for more patients worldwide.

• Our E2E Platform adds innovative solutions for improved development, safety and efficacy of our TCR-guided immunotherapies.

11:30 am The Best of Both Worlds: How TCRs Synergize with the Innate Activity of NK Cells

Synopsis

  • Addressing tumor heterogeneity with dual targeting
  • Avoiding tumor escape mechanisms 
  • Delivering an allogeneic off-the-shelf NK cell therapy

Improving Efficacy to Reinvent Durability & Persistence in the Solid Tumor Microenvironment

12:00 pm Panel Discussion: A Commercial TCR-T & TCR Bispecific – What’s Next?

Synopsis

• Discussing engineering methods to alter T-cell or bispecific properties to increase trafficking to tumor sites and enable prolonged killing

• Inhibiting immune suppression pathways to improve cell survival

• Considering implications of multi-engineering on cell viability and patient safety to mitigate adverse effects

12:45 pm Using a Novel TGF-beta Switch to Prevent Exhaustion of T-Cells in the Solid TME

  • Felix Lorenz Co-founder, Chief Executive & Scientific Officer, Captain T Cell

Synopsis

• Introduction of a novel TGF-beta Switch Receptor: explaining how the novel switch modulates TGF-beta signaling to enhance T-cell functionality within the hostile solid tumor microenvironment (TME)

• Preventing T-cell exhaustion: demonstrating how this approach effectively prevents T-cell exhaustion, enabling repeated killing

• Implications for advanced Immunotherapies: discussing the integration of this technology into the toolbox of technologies of Captain T Cell to develop more effective treatments for solid tumors

1:15 pm Lunch Break & Networking

2:15 pm Integrating a Co-Stimulatory CD8 Co-Receptor & a Tailored Switch Receptor to Boost Persistence and Anti-Tumor Activity

Synopsis

• Identifying inhibitory factors in the tumor microenvironment by large-scale tumor screening and translating these into activating signals through switch receptors

• Leveraging inhibitory switch receptors to boost engraftment during TCR-T cell trafficking

• Equipping cells with a costimulatory CD8 co-receptor to overcome lack of co-stimulatory signaling in the tumor

2:45 pm Affini-T Platform Technologies Enable the Generation of Potent & Tolerable TCR-T Cells

  • Gary Shapiro Vice President, Discovery Biology, Affini-T Therapeutics

Synopsis

• TAILOR TCR discovery platform uses predictive algorithms to identify highly functional and specific TCRs against diverse targets

• TUNE synthetic biology platform programs cell persistence in the TME to enhance durability with switch receptors, co-receptors, and other armoring technologies

• THRIVE engineering and manufacturing platform allows for scalable manufacturing with gene editing technologies to generate a robust engineered product with > 95% central memory / stemness phenotype

Transforming Clinical Strategy to Efficiently Progress the Next Wave of Therapies

3:15 pm RoundTable: Reflecting on Current Clinical Strategy to Enable Smooth Trial Recruitment & Progression

Synopsis

• Evaluating best practice to select a target indication based on therapeutic approach

• Discussing challenges in patient screening and engagement to facilitate recruitment in early- and late-stage trials

• Sharing regulatory experiences to distinguish a clear path into and through the clinic

• Discussing manufacturability and scalability to cater to the growing patient population

4:00 pm Strategies for Clinical Dose Selection of CDR404: A MAGE-A4/HLA-A2 Antibody-Based T-Cell Engager

Synopsis

• Using Quantitative Systems Pharmacology (QSP) modeling for dose escalation and FIH study design for CDR404

• We discuss the key preclinical pharmacological data used for generation of a QSP model for CDR404

• Forward-looking perspectives and next generation antibody-based TCEs targeting peptide-HLA on cancer cells

4:30 pm Close of Conference Day Two

DAY ONE
FULL EVENT GUIDE